In pursuit of the normal progressor: the holy grail for ALS clinical trial design?

Ruben P. A. van Eijk1 Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands and ;2 Biostatistics & Research Support, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the NetherlandsCorrespondence[email protected]

Leonard H. van Den Berg1 Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands and

"In pursuit of the normal progressor: the holy grail for ALS clinical trial design?." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21(1-2), pp. 1–2

This article is related to:

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Data availability statement

The data that support the findings of this study are openly available in PRO-ACT at https://nctu.partners.org/ProACT, version December 2015.

Declaration of interest

The authors declare that they have no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

In pursuit of the normal progressor: the holy grail for ALS clinical trial design?

Information for

Open access

Opportunities

Help and information

In pursuit of the normal progressor: the holy grail for ALS clinical trial design?

Data availability statement

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature